Team

I receieved the following spam this morning to my E-mail that was harvested from this site or from a bot on someone's system. So, to remind everyone all about spam and my aversion to it, Look at the bullshit I received following this.
Posting images to this site or any site form your computer is a big opening for others into your system. Consider this!
Robert...about yahoo AGAIN.

****

FOR IMMEDIATE RELEASE

PROTOKINETIX INC. (PKTX : OTCBB)

Vancouver, British Columbia, October 29, 2003

PROTOKINETIX INCORPORATED
http://finance.yahoo.com/q?s=PKTX.OB&d=t

DR. JOHN TODD STATES HOW VALIDATION TRIALS WILL FAST
TRACK THERAPEUTIC DEVELOPMENT.

(OTCBB: PKTX) - As a follow-up to last week’s
announcement of validation trials, Dr. John Todd,
president of ProtoKinetix, states how this will fast
track the development of therapeutic products. By
entering into a relationship with the Georges Pompidou
Hospital,ProtoKinetix has the ability to access a vast
pool of credible researchers in the European community.

European Hospital Georges Pompidou, of Paris, France,
is the most modern full-service hospital in Europe.
Completed only 3 years ago, it has become the flagship
of European health care and is already one of the most
advanced hospitals and research centers in the world.

A member of ProtoKinetix scientific advisory board,
Dr. Ricardo Moro, has demonstrated that the presence
of alpha fetaprotein in the human body (other than
in pregnant women) is a non-specific indicator of
the existence of cancer in the system. He believes,
as does ProtoKinetix, that the RECAFTM receptor site
exists as a specific receptor site for alpha fetaprotein.

The development of monoclonal antibodies to the highly
specific carbohydrate molecule attached to the RECAFTM
protein will allow the engineering of a Super-antibody
created to target and kill malignant cells.

Following these trials, ProtoKinetix will generate
antibodies to the RECAFTM receptor site and identify
those that are most specific and do not have an
affinity to healthy cells.

The conversion of the selected antibody to a humanized
targeted killer is a function of molecular engineering
that is readily attainable.

ProtoKinetix Inc.
ProtoKinetix Inc. is a therapeutic development company
whose mission is to develop effective biological
therapeutics for the treatment of malignancies.

The company has focused on the new generation of
monoclonal antibodies termed “super-antibodies”.
We have been licensed to use super-antibody technology
to produce antibodies expressed against the RECAF
receptor site on the cell surface of many malignancies.
ProtoKinetix will use this technology to create
therapeutic antibodies to help in the treatment
of cancers. ProtoKinetix is positioned to leverage
existing products and intellectual properties through
a series of collaborative relationships into effective
therapeutic agents.

The Private Securities Litigation Reform Act of 1995
provides a "safe harbor" for forward -looking
statements. Some information included in this
press release contains statements that are forward-
looking. Such forward-looking information involves
significant risks and uncertainties that could
affect anticipated results in the future and,
accordingly, these results may differ materially
from those expressed in any forward-looking statements
made by or on behalf of the Company. For a description
of additional risks and uncertainties, please refer
to the Company's filings with the Securities and
Exchange Commission.

To be expunged from our list send mail to
plqmx@yahoo.com